Company: SXTPW
Filing Date: 2025-01-08
Form Type: 8-K
Source: 0001213900-25-002070
Chunk: 0

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-01-08
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

On January 8, 2025, 60 Degrees Pharmaceuticals,
Inc. (the “ Company”) issued a press release announcing that it enrolled its first patient in NCT06478641, an expanded access
clinical study intended to confirm the activity of tafenoquine in treating patients with persistent babesiosis who have failed standard
of care treatment and are at high risk of experiencing a relapse. A copy of the Company’s press release is furnished as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information set forth under this Item 8.01,
including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific
reference in such a filing.

Item 9.01 Financial Statements and Exhibits.